Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00454558
Status:
COMPLETED
Last Update Posted:
2015-10-16
First Post:
2007-03-28
Brief Title:
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
A Multicenter Non-randomized Non-blinded Noncontrolled Study to Investigate the Impact of Multiple Doses of BAY 63-2521 on Safety Tolerability Pharmacokinetics and Pharmacodynamics in Patients With Pulmonary Hypertension in a 12-week 3 Times a Day Individual Dose Titration Scheme
Status:
COMPLETED
Status Verified Date:
2015-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to demonstrate the feasibility of an individual dose titration scheme based on the systolic blood pressure with a dose range from 10 mg TID to 25 mg TID Patients suffering from chronic thromboembolic pulmonary hypertension CTEPH or pulmonary arterial hypertension PAH will be included After diagnosis by an expert center patients receive medication three times a day starting with 10 mg TID The first tablets are given in the hospital then the patients are allowed to go home and take the medication at home After 2 weeks patients return to the hospital for an ambulatory visit and the dose may be increased based on the actual condition of the patient blood pressure and adverse events Several measurements will be performed to test the efficacy of the drug and whether there are any unwanted reactions to the drug blood tests ECG 6 minute walk test imaging by Echo quality of life scores The dose of the drug will then be increased further until unwanted effects may occur or the blood pressure drops to low The highest dose tested will be 25 mg TID After 12 weeks the patient is going to stay in the hospital again and a right heart catheter is performed to examine the changes in hemodynamics after 12 weeks of treatment with the drug If the patients give their consent they can enter a long-term extension trial continuing on BAY63-2521 with the dose reached after 12 weeks Every 3 months an ambulatory visit at the specialist center will be performed including measurements of safety blood tests ECG clinical assessment and efficacy 6 minute walk test Borg dyspnea scale NT-pro BNP Blood tests and ECG have been removed begin of 2013 as safety parameter by amendment 7 furthermore Borg dyspnea score and NT-proBNP have been removed as efficacy parameter
Initially the inclusion of ten patients suffering from chronic thromboembolic pulmonary hypertension CTEPH or pulmonary arterial hypertension PAH was planned Later on the patient number was amended and 75 patients entered the trial
Furthermore the trial duration was extended and a long term treatment with BAY63-2521 was offered to the patients Finally 68 patients moved over to the long term extension period of the trial
Initially the inclusion of ten patients suffering from chronic thromboembolic pulmonary hypertension CTEPH or pulmonary arterial hypertension PAH was planned Later on the patient number was amended and 75 patients entered the trial
Furthermore the trial duration was extended and a long term treatment with BAY63-2521 was offered to the patients Finally 68 patients moved over to the long term extension period of the trial
Detailed Description:
Specification of primary outcome measures for long-term safety and tolerability Adverse events blood pressure and heart rate 12 lead ECG clinical chemistry and hematology Troponin I
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-003520-10 | EUDRACT_NUMBER | None | None |